These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37086388)

  • 1. Investigating the correlation between COVID-19 and the progression of chronic liver disease.
    Philips CA; Madhu D; Augustine P
    Expert Rev Gastroenterol Hepatol; 2023; 17(6):603-613. PubMed ID: 37086388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of COVID-19 on patients with compensated chronic liver diseases.
    Ji D; Zhang D; Yang T; Mu J; Zhao P; Xu J; Li C; Cheng G; Wang Y; Chen Z; Qin E; Lau G
    Hepatol Int; 2020 Sep; 14(5):701-710. PubMed ID: 32734407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 infection and liver involvement.
    Luo M; Ballester MP; Soffientini U; Jalan R; Mehta G
    Hepatol Int; 2022 Aug; 16(4):755-774. PubMed ID: 35767172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
    Paik JM; Eberly KE; Kabbara K; Harring M; Younossi Y; Henry L; Verma M; Younossi ZM
    Ann Hepatol; 2023; 28(4):101108. PubMed ID: 37088421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
    Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients.
    Naeem M; Bano N; Manzoor S; Ahmad A; Munawar N; Razak SIA; Lee TY; Devaraj S; Hazafa A
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and liver injury: An ongoing challenge.
    Papagiouvanni I; Kotoulas SC; Pataka A; Spyratos DG; Porpodis K; Boutou AK; Papagiouvannis G; Grigoriou I; Vettas C; Goulis I
    World J Gastroenterol; 2023 Jan; 29(2):257-271. PubMed ID: 36687117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease.
    Elfeki MA; Robles J; Akhtar Z; Ullah F; Ganapathiraju I; Tran C; Inman C; Collin SM; Rosa R
    Dig Dis Sci; 2022 Jul; 67(7):3333-3339. PubMed ID: 34173917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and management issues of NAFLD-related HCC: what we know so far.
    Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature.
    Almomani A; Kumar P; Onwuzo S; Boustany A; Krishtopaytis E; Hitawala A; Alshaikh D; Albakri A; Hussein L; Hussein E; Asaad I
    J Gastroenterol Hepatol; 2023 Feb; 38(2):269-273. PubMed ID: 36328950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural History of Cirrhosis: Changing Trends in Etiology Over the Years.
    Idilman R; Aydogan M; Oruncu MB; Kartal A; Elhan AH; Ellik Z; Gumussoy M; Er R; Ozercan M; Duman S; Toruner M; Cinar K; Soykan I; Beyler AR; Ozkan H
    Dig Dis; 2021; 39(4):358-365. PubMed ID: 33142287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
    Lai J; Wang HL; Zhang X; Wang H; Liu X
    Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome and chronic liver disease.
    Rosselli M; Lotersztajn S; Vizzutti F; Arena U; Pinzani M; Marra F
    Curr Pharm Des; 2014; 20(31):5010-24. PubMed ID: 24320032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.
    Li P; Liu Y; Cheng Z; Yu X; Li Y
    Biomed Pharmacother; 2022 Oct; 154():113568. PubMed ID: 36029543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease.
    Hartl L; Haslinger K; Angerer M; Semmler G; Schneeweiss-Gleixner M; Jachs M; Simbrunner B; Bauer DJM; Eigenbauer E; Strassl R; Breuer M; Kimberger O; Laxar D; Lampichler K; Halilbasic E; Stättermayer AF; Ba-Ssalamah A; Mandorfer M; Scheiner B; Reiberger T; Trauner M
    Hepatology; 2022 Dec; 76(6):1563-1575. PubMed ID: 35596929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.